Medical imaging specialist Guerbet announces a strategic partnership with Nuclidium aimed at advancing the latter's copper-based diagnostic and therapeutic radiopharmaceuticals.

This partnership will give Nuclidium access to Guerbet's extensive knowledge and network in diagnostic imaging, production and clinical trials, facilitating the progression of its theranostic candidates towards commercialization.

In this context, Guerbet has made a non-exclusive strategic investment in Nuclidium, whose Board of Directors will include François Nicolas, Guerbet's Director of Research, Development, Innovation and AI, as an observer.

Copyright (c) 2024 All rights reserved.